Noesis turns fragmented cancer data into a single, explainable patient-state measure — then uses the journey between appointments to create new measurements that make that score more powerful over time.
Three claims about what Noesis is, and three about what it keeps being mistaken for.
A mechanistic prognostic measure of a cancer patient’s evolving clinical state. It combines performance status, labs, tumour markers and imaging through explicit formulas — not an opaque black box.
Identify who is more likely to deteriorate sooner, who needs attention first, and how to stratify patients more intelligently in clinical trials.
A measurement instrument that reinforces itself: new data improves the Score, and the Score gives new measurements clinical and commercial value.
Each result comes from physical measurements and stated formulas. The model is auditable, explainable, and can show exactly why a result moved.
It captures physiology, symptoms, function and observations the medical record misses — the signal that exists between appointments and nowhere else.
New measurements improve the Score; the Score gives those measurements value. Neither half is as useful alone.
A doctor sees fifteen minutes of your test results. Your family sees your life, but not your labs. Nobody holds the whole picture — and nobody is there for the time in between, where a scan can read "stable" while a person quietly slips, unnoticed until a crisis.
Results now reach your phone the moment they exist — often before your doctor has read them, alone and late at night, in words meant for a specialist. NoesisCare is there in that moment.
The scariest moment isn’t the appointment. It’s being alone with the result afterward — at 11pm, on a phone, with no one to explain it.
NoesisCare meets people at the hardest moments and turns them into something you can act on.
Turn a frightening result into plain words the moment it lands — and say whether it's worth a call today. Sit with you through the wait for a scan.
Quietly track how you're doing and alert your care team before a crisis or an emergency-room visit — not after.
✓ the part with the strongest evidenceThe fear of it coming back, the insurance fights, the cost of it all — and the caregiver carrying it too. You shouldn't hold any of it alone.
Scattered signals become one clear score. The score becomes awareness. Awareness becomes action — and every action sharpens the next read.
A device reads your body around the clock. It can't read your fear. Both go in — on their own lines, never held against you.
One patient, one Tuesday, one score. Three people need something different from it — pick one and see what they actually get.
Your kidney markers moved and inflammation is up. Not an emergency tonight — but worth a call tomorrow.
Illustrative data — one score, three views.
The near-term asset is the Score. The long-term asset is the measurement network around it.
A sponsor-usable prognostic biomarker for trial stratification, enrichment and discontinuation-risk management.
The near-term wedgeA patient and caregiver platform capturing longitudinal signals unavailable in conventional trial and EHR datasets.
The data moatClinician prioritisation and safety alerts that convert measurement into decisions — operational, not observational.
Where it earns its keepSponsor-funded use, external validation, and a defined regulatory context of use.
The Score updates as new clinical and longitudinal measurements arrive, rather than waiting for the next visit.
If prospectively validated, the same state variable can connect trials, clinicians, navigation and payers.
The moat is not the formula alone. It is the combination of a mechanistic Score, a growing longitudinal dataset, patient and caregiver measurement, clinical workflow, validated outcomes and an accumulating regulatory history.
A competitor can copy an interface. It cannot instantly recreate the data-generating network and the evidence base behind it.
Biomarker revenue — sponsor licensing, trial-level fees and per-patient use.
Navigation revenue — reimbursed workflows can help fund data collection.
Compounding value — each deployment expands the proprietary longitudinal evidence base.
Proven: retrospectively prognostic; outperforms ECOG and Köhne in the reported held-out comparison.
Next: independent external validation, prospective deployment, regulatory strategy, and first pharma and CRO pilots.
To prove: clinical utility, improved outcomes, and whether new channels materially raise performance.
Noesis is not another cancer app: it is building an explainable patient-state biomarker, and the measurement network that can continuously make that biomarker more valuable.
NoesisCare is being built with patients, caregivers, and clinicians. If that's you, we'd like to talk.
We've received your request. NoesisCare is launching later this year, and someone from our team will be in touch with you soon. You're not navigating this alone.